Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Neurology. 2010 Jan 5;74 Suppl 1:S31-40. doi: 10.1212/WNL.0b013e3181c97ed3.

Monoclonal antibodies in MS: mechanisms of action.

Author information

  • 1Neuroimmunological Diseases Unit, National Institute NIH, Bethesda, MD 20892, USA. Bibi.Bielekova@nih.gov


The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk